| Added by | pmartino |
|---|---|
| Group name | EquipePM |
| Item Type | Journal Article |
| Title | Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort |
| Creator | Carbasse et al. |
| Author | Clément Carbasse |
| Author | Fanny Leenhardt |
| Author | William Jacot |
| Author | Caroline Perrier |
| Author | Marie Viala |
| Abstract | INTRODUCTION: Oral targeted therapies (OTTs) are widely used for cancer management. However, there is no consensus on OTT dose adaptation in older patients with cancer. METHODS: This noninterventional, retrospective study was a real-life assessment of dose adaptation for six OTTs (afatinib, everolimus, palbociclib, pazopanib, sorafenib and sunitinib), at baseline and during treatment, and the reasons for the changes, in ?70-year-old patients treated between February 2016 and August 2019. Data were compared with univariate models fitted with all variables. RESULTS: Among the 986 patients treated with OTT, the group of ?70-year-old patients (n?=?122) received afatinib (15.6%), everolimus (14.8%), palbociclib (50.8%), pazopanib (9.8%), sorafenib (5.8%) or sunitinib (3.2%). At baseline, the prescribed OTT dose was adapted (reduction) in 29% of ?70-year-old patients (35/122). These 35 patients were significantly older (mean age 80 vs 74?years, P? |
| Publication | British Journal of Clinical Pharmacology |
| Volume | 88 |
| Issue | 7 |
| Pages | 3370-3377 |
| Date | 2022-07 |
| Journal Abbr | Br J Clin Pharmacol |
| Language | eng |
| DOI | 10.1111/bcp.15285 |
| ISSN | 1365-2125 |
| Short Title | Oral targeted therapy dose adaptation in older patients with cancer |
| Library Catalog | PubMed |
| Extra | PMID: 35178745 |
| Tags | Administration, Oral, Afatinib, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Renal Cell, clinic, Everolimus, Humans, Indoles, Kidney Neoplasms, oncogeriatric, oral targeted therapy, Pyrroles, Retrospective Studies, Sorafenib, Sunitinib, Treatment Outcome |
| Date Added | 2023/02/25 - 11:51:50 |
| Date Modified | 2023/04/06 - 18:08:58 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
